Based on Kancera’s existing assets, the goal is to conclude agreements with internationally established pharmaceutical companies for the sale of the pharmaceutical projects currently in progress.
In addition, the company will also continue to initiate the development of new projects. Access to new pharmaceutical projects for refinement and onward sale is secured through a broad, international industrial and academic network, cutting-edge expertise within preclinical pharmaceutical development and early testing out of effect in clinically relevant tumor samples, and also an experienced, highly qualified business development team that builds international partnerships.
Kancera has knowledge and methods that allow the actual effect of a drug candidate in clinical preparations from patients to be demonstrated at an early stage – in the preclinical phase – with a good level of certainty and predictability. The focus is on the drug candidate’s ability to overcome the disease’s resistance to treatment, which is one of the main causes of deaths from cancer.